Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025 ...

Moreover, in both allogeneic and syngeneic tumor models, miltefosine significantly enhanced the tumor-clearing capacity of CAR-T cells and T cells. The drug screening platform can assess FDA ...

IAR037 is a novel CD40/PD-L1 bispecific antibody, which simultaneously activates CD40 and blocks PD-1/L1, demonstrating potent anti-tumor efficacy in PD-1-resistant syngeneic mouse models and synergy ...

IAR037 is a novel CD40/PD-L1 bispecific antibody, which simultaneously activates CD40 and blocks PD-1/L1, demonstrating potent anti-tumor efficacy in PD-1-resistant syngeneic mouse models and ...